A pooled analysis of bone marrow micrometastasis in breast cancer.

By S. Braun, F. Vogl, B. Naume, W. Janni, Michael P. Osborne, R. Coombes, G. Schlimok, I. Diel, B. Gerber, G. Gebauer and 12 more. New England Journal of Medicine, 2005

1,365 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/6d9b402acdca80ea91177f9df8f6f4f246b24a81

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Massagué
2. P. Paterlini-Bréchot
3. Robert A. Gatenby
4. M. Wicha
5. E. Batlle
6. G. Gupta
7. N. Benali
8. H. Horlings

In Oncology

1. J. Massagué
2. M. Wicha
3. Larry Norton
4. Suling Liu
5. E. Batlle
6. Thordur Oskarsson
7. G. Dontu
8. P. Paterlini-Bréchot

In Pathology and Forensic Medicine

1. J. Massagué
2. G. Gupta

Citations in the corpus

• Environment-mediated drug resistance: a major contributor to minimal residual disease (2009, background): “For example, the presence of bone marrow micrometastasis in around 30% of patients with breast cancer at the time of diagnosis is a strong predictor of relapse, despite aggressive treatmen”
• Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients (2009, background): “Although the prognostic value of these cells has been shown by several groups [3-7], it is assumed that the metastatic potential of a tumor is based on the presence of a low number of stem cell-like tumor cells that have been identified in tumor tissue to be the active source of metastatic spread [8”
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, background): “Recently, an analysis of pooled data from several prospective studies has provided enormous power to evaluate such subsets.(295) In every case, the presence of bone marrow micrometastases was associated with a statistically significantly higher risk of recurrence and death.”
• Cancer stem cells: an old idea--a paradigm shift. (2006, background): “However, after 10 years, up to 50% of these have patients have not developed clinically relevant macroscopic disease (44).”
• Tumor Metastasis: Molecular Insights and Evolving Paradigms (2011, neutral): “harbor significant numbers of disseminated tumor cells in their blood, bone marrow, and distant organ sites upon initial presentation in the oncology clinic (Braun et al., 2005; Nagrath et al., 2007; Pantel et al., 2008).”
• EMERGING BIOLOGICAL PRINCIPLES OF METASTASIS (2017, neutral): “And while it is difficult to formally prove that a metastatic colony directly developed from a preexisting dormant DTC, the presence of DTCs in the bone marrow is clearly correlated with an increased risk of eventual clinical recurrence (Braun et al., 2005).”
• Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype (2006, background): “(3) in a large number of patients analyzed shows that although the presence of DTC is associated with a poor prognosis, a significant proportion of patients still do well even after 10 years.”
• Metastatic Stem Cells: Sources, Niches, and Vital Pathways (2014, background): “Those that survive the ordeal may remain alive for decades but still fail to form clinically manifest lesions (Braun et al., 2005; Janni et al., 2011).”
• Cancer metastasis: building a framework. (2006, background): “For several types of carcinomas, solitary tumor cells can be detected in the bone marrow years before the development of overt metastasis (Braun et al., 2005).”